Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, and Ian Tarpey
- Intervet Inc., Madison, NJ
The present disclosure describes antibodies including caninized antibodies against canine PD-L1 with specific properties. The document relates to epitopes of canine PD-L1 that bind to these antibodies, as well as to anti-canine PD-L1 antibodies that bind these epitopes, and to the use of the caninized anti-canine PD-L1 antibodies in the treatment of cancer in dogs.
CovalX Technology Used
Mass spectroscopy was used to identify discontinuous epitopes that may be recognized by anti-canine PD-1. CovalX completed the epitope mapping of canine PD-1. Through this method, researchers were able to identify portions of epitopes that were recognized by mAbs. For example, mAb 4F9 recognizes an epitope that is located in the extracellular domain of canine-PD-1 (amino acid SEQ ID NO:82 and SEQ ID NO:83). mAb 5F12 also recognized an epitope with the amino acid sequence 82. It is interesting to note that the epitopes of canine PD-L1 found through the CovalX epitope mapping service correspond to those in the human PD-L1.